Key Findings From BOND-003: Cretostimogene Grenadenorepvec in NMIBC
May 3rd 2024Mark D. Tyson, II, MD, MPH, discusses the safety and efficacy findings from the BOND-003 trial of cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Watch
LITESPARK-005: Belzutifan in Previously Treated Advanced Clear Cell RCC
Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.
Watch
Clinical Trials Evaluating Lenvatinib Plus Everolimus in Advanced Renal Cell Carcinoma
The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.
Watch
Background, Methods, and Design of BOND-003 in NMIBC
May 3rd 2024Mark D. Tyson, II, MD, MPH, discusses the background of the phase 3 BOND-003 study evaluating cretostimogene grenadenorepvec in patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Watch
Emerging Therapies for Refractory cGvHD: Potential Advantages of Axatilimab
May 3rd 2024The final segment explores the potential role of axatilimab, a novel agent, in the management of refractory cGvHD, highlighting its mechanism of action and potential efficacy compared to existing treatment options.
Watch
Quality of Life + Clinical Monitoring Outside the Transplant Center
April 30th 2024Yi-Bin Chen, MD, proposes a strategy to enhance patients' quality of life by utilizing virtual monitoring as an alternative to requiring patients to travel to a transplant center, which includes regular remote assessments of blood work, such as liver function tests, lipid panels, and immunoglobulin levels.
Watch
Second-Line Medications and Toxicities in GVHD
April 30th 2024A medical expert delves into various aspects of second-line therapies, including dose reductions, potential adverse reactions, and the possibility of transfusions, all of which are important considerations when managing patients on second-line treatments.
Watch
Emerging Therapies for Chronic Graft-Versus-Host Disease
April 26th 2024This segment of the virtual tumor board presentation focuses on the clinical development and use of emerging therapies, specifically Belumosudil, for the management of chronic graft-versus-host disease (cGvHD) following hematopoietic stem cell transplantation.
Watch
TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.
Watch
RCC: Treatment Goals in the Third-Line Setting
Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.
Watch
Adverse Event Profile and Tolerability of Fruquintinib Based on FRESCO-2 Trial
April 25th 2024Arvind Dasari, MD, explores the adverse event profile of Fruquintinib, highlighting its apparent tolerability, while emphasizing the importance of gathering real-world data to further assess the adverse event profile of this medication in clinical practice.
Watch
FRESCO-2 Study Design Overview
April 25th 2024Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.
Watch
Overall Survival and Progression Free Survival in the FRESCO-2 Trial
April 25th 2024Arvind Dasari, MD, examines the progression-free survival and overall survival data from the FRESCO-2 trial, comparing the results to the original FRESCO trial, and discussing the implications for the treatment of heavily pretreated metastatic colorectal cancer patients.
Watch